Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AbbVie: Rinvoq And Skyrizi Will Bridge US Humira Sales Erosion Through 2025

Executive Summary

Continuing its longstanding effort to assure investors about growth past Humira’s US patent expiry in 2023, the pharma outlined label-expansion and market share plans for its two newer immunology drugs.

You may also be interested in...



AbbVie Ups Its IBD Game With Latest Crohn’s Data For Rinvoq

The leader in inflammatory bowel disease via Humira, AbbVie awaits a US FDA decision in June for Skyrizi in Crohn’s disease and plans to add a Crohn’s indication to Rinvoq’s ulcerative colitis approval.

AbbVie Focuses On Humira’s Formulary Positioning Ahead Of Biosimilars

A year out from the US patent expiration for top-seller Humira, AbbVie is negotiating for formulary position alongside biosimilars. Analysts said success there could delay some patent cliff pain until 2024.

AbbVie Remains Confident About Rinvoq Despite Coming Safety Labeling Update

A safety-related FDA revision of Rinvoq’s label in rheumatoid arthritis is a perceived threat to the JAK inhibitor’s growth, but it and fellow immunology asset Skyrizi produced another strong sales quarter.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143488

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel